supported,in part,by grants from the State Project for Essential Drug Research and Development(No.2019ZX09301132,China);National Natural Science Foundation of China(Nos.82060562 and 82072340);the Scientific and Technological Innovation Major Base of Guangxi(No.2018-15Z04,China);Guangxi Key Research and Development Project(No.AB20117001,China);Guangxi Natural Science Foundation(No.2018JJA140524,China)。
Hepatocellular carcinoma(HCC)is a common malignant tumor with poor prognosis and high mortality.In this study,we demonstrated a novel vaccine targeting HCC and tumor neovascular endothelial cells by fusing recombinant...